Brian Matesic
Principal @ Norwest
San Francisco Bay Area, United States
Brian Matesic is a Principal at Norwest Venture Partners. He previously worked as the Principal of Blackstone Life Sciences at the Blackstone Group and Engagement Manager at McKinsey and Company. Brian attended Stanford University School of Medicine, Harvard Business School, and the University of Illinois Urbana-Champaign.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Brian Matesic invests in
Stages Brian Matesic invests in
Countries Brian Matesic invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (75%)
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Therapeutics 1 (25%)
- Pharmaceutical 1 (25%)
Stage
- Series A 3 (75%)
- Series B 1 (25%)
Country
- United States 3 (75%)
- Switzerland 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology. | $150M / Series B / Oct 07, 2026 | ||
| Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M / Series A / Jun 09, 2025 | ||
| Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M / Series A / Mar 03, 2025 | ||
| Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline. | $120M / Series A / Jan 10, 2025 |
Co-Investors
Access Biotechnology
1 deal together
Atlas Venture
1 deal together
BB Biotech
1 deal together
BOLD Longevity Growth Fund
1 deal together
Boyu Capital
1 deal together
Broadview Ventures
1 deal together
About Norwest
Norwest is a global venture and growth equity investment firm managing more than $15.5 billion in capital. Since its inception, Norwest has invested in more than 700 companies and currently partners with more than 250 companies in its venture and growth equity portfolio. The firm invests in early- to late-stage businesses across key sectors with a focus on enterprise, healthcare and consumer. The Norwest team offers a deep network of connections, extensive operating experience, and a wide range of impactful services to help CEOs and founders scale their businesses. Norwest has offices in Menlo Park and San Francisco, Calif.; Mumbai, India; and Tel Aviv, Israel.
Norwest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brian Matesic
Principal
|
|||
Dave Zilberman
General Partner
|
|||
David Su
Partner
|
|||
Dror Nahumi
General Partner
|
|||
Edward Yip
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brian Matesic invest in?
Brian Matesic invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brian Matesic?
Public channels for Brian Matesic include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brian Matesic last invest?
The most recent investment recorded for Brian Matesic closed in Oct 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
